ALK and non-small cell lung carcinoma: It is estimated that the incidence of ALK rearrangements in unselected NSCLC populations is 2%–7% [9], [11], [12], indicating that only a small proportion of NSCLC patients will benefit from ALK kinase inhibitors, and the accurate and timely identification of these patients will have important therapeutic implications.